Type 2 diabetes is a very common worldvide disorder. A good glycemic controll is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.
|Translated title of the contribution||A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)|
|Number of pages||5|
|Publication status||Published - Jun 1 2010|
ASJC Scopus subject areas